- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02201693
Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease (CD-HOPE)
Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Enteral nutrition (EN) is a highly efficacious treatment option for Crohn's disease (CD). In children, exclusive EN is considered first choice therapy to induce remission in pediatric CD, as highlighted in the recent ESPGHAN-ECCO guidelines. Several meta-analyses showed that the anti-inflammatory potential of EEN is comparable to the effects of steroids. In addition, children with CD often have marked growth retardation and EEN is one of the most efficacious treatment options to induce catch-up growth in these patients. There is convincing data indicating that EN is highly efficacious when given on an exclusive basis, while the use of partial EN is markedly less effective to induce remission in active Crohn's disease as compared to exclusive EN. Recently, it was suggested that exclusive EN has a dominant effect on the intestinal microbiota, which contributes to the induction of remission. There exists several strategies to maintain remission in children with CD, but there is no clear consensus on which maintenance treatment to follow. There are some indicators to believe that enteral nutritional therapy might play also a significant role as maintenance therapy for CD. Given the fact that many centers use a top-down approach with the introduction of immunosuppressors and/or biologics at/or shortly after diagnosis, the investigators wanted to test the possibility of a treatment option to efficiently maintain remission with less (or no) side effects based on enteral nutrition to avoid the early use of immunosuppressors.
It's a French multicenter, prospective, randomized study with PROBE (prospective randomized open blind end-point) evaluation. Randomization will be performed in a blinded and centralized manner, allocating patients to one of the two treatment groups :
- ARM A : Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
- ARM B: MODULEN IBD supplementation (25% of caloric requirements) alone
A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
A total of four visits (including final visit) are scheduled for this trial over a period of 12 months at a rhythm of every three months (+/- 2 weeks) for all patients. The study visit will happen during scheduled routine visits, necessary for the routine care of CD patients. Each visit comprises a routine clinical evaluation. The assessment of maintenance of remission is particularly important (wPCDAI<12.5 points), a routine lab analysis including fecal calprotectin is required at each visit. In addition, all relevant medical or other events will be recorded. Only for patients who participate in the annex studies an additional stool sample (microbial analysis) is required. At M9 visit, follow-up endoscopy (M12+/- 6weeks) and entero-MRI (M12+/- 6 weeks) will be programmed as part of the routine surveillance of patients on maintenance therapy, allowing to adjust treatment in the following if necessary. Compliance to treatment will be monitored by recordings of daily MODULEN IBD intake during 2 week periods on the E-system. A quality of life E-questionnaire will be filled out one day prior to each visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker - Enfants malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 6-18 years
- Confirmed Crohn's disease (L1, L2, L3+/- L4a/b)
- new-onset disease or acute relapse treated with enteral nutrition
- responding to induction therapy with exclusive enteral nutrition with complete clinical remission at inclusion visit (wPCDAI<12.5)
- completed cycle of induction therapy of at least 6 weeks (6-12 weeks)
- biological treatment by Remicade has to be stopped at least 8 weeks prior to inclusion
- "wash out" of corticosteroids, immunosuppressors and treatment by Humira of minimally 4 weeks prior to inclusion
- 5-ASA and derivates have to be stopped at least at screening visit
- Antibiotics must be stopped at least 2 weeks prior to inclusion
- Informed and signed consent
Exclusion Criteria:
- Patients with B2 or B3 disease behavior (intestinal/colonic stenosis (including ileo-caecal valve), intrabdominal abscess, fistulizing disease)
- Patients not in remission on induction therapy (wPCDAI>12.5)
- Patients with isolated and severe perianal disease
- Patients requiring surgical therapy at inclusion
- Ongoing steroid medication
- Ongoing immunosuppressor or biologics therapy
- No informed consent
- Currently participating or having participated in another interventional clinical trial during the last 4 weeks prior to the beginning of this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cyclic exclusive MODULEN IBD
Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
|
2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx.
2-2.5L/day).
25% of daily caloric requirements, approx.
500mL/day
|
Experimental: MODULEN IBD supplementation (25% of caloric requirements)
MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
|
2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx.
2-2.5L/day).
25% of daily caloric requirements, approx.
500mL/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The first relapse
Time Frame: 12 months
|
Assessed with wPCDAI
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical remission
Time Frame: 12 months
|
Assessed with wPCDAI, CDAI, PGA
|
12 months
|
Time to the first relapse
Time Frame: until month 12
|
Assessed with wPCDAI, CDAI, PGA
|
until month 12
|
Variation of wPCDAI,
Time Frame: until month12
|
Assessed with wPCDAI
|
until month12
|
Endoscopic remission
Time Frame: month 12
|
CDEIS
|
month 12
|
Transmural healing
Time Frame: Month 12
|
MRI
|
Month 12
|
Calprotectin
Time Frame: until month12
|
Fecal sample
|
until month12
|
Quality of life analysis
Time Frame: Until Month 12
|
E-questionnaire
|
Until Month 12
|
Growth pattern
Time Frame: Until Month 12
|
Z-Score
|
Until Month 12
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Franck Ruemmele, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P130302
- 2013-A01473-42 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on MODULEN IBD
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MICALIS InstituteRecruiting
-
Prof. Arie LevineCompletedCrohn's DiseaseCanada, Israel
-
University Hospital of North NorwayUniversity of TromsoActive, not recruiting
-
Jennifer JonesTakeda; 90 Second HealthRecruitingCrohn Disease | Ulcerative Colitis | IBDCanada
-
Leiden University Medical CenterMedical Center Haaglanden; Voeding LeeftActive, not recruitingFatigue | Inflammatory Bowel DiseasesNetherlands
-
Hôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France; NestléUnknownCrohn's Disease | PediatricFrance
-
Children's Hospital Medical Center, CincinnatiCompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | IBDUnited States
-
PredictImmune LtdCrohn's and Colitis FoundationRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | IBDUnited States
-
London North West Healthcare NHS TrustKing's College London; Queen Mary University of LondonCompletedFecal Incontinence | Inflammatory Bowel Disease (IBD)United Kingdom